149 related articles for article (PubMed ID: 36396101)
1. Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia.
Zhou H; Jiang Y; Huang Y; Zhong M; Qin D; Xie C; Pan G; Tan J; Deng M; Zhao H; Zhou Y; Tang Y; Lai Q; Fang Z; Luo Y; Jiang Y; Xu B; Zha J
Cancer Lett; 2023 Feb; 554():215997. PubMed ID: 36396101
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia.
Xie C; Zhou H; Qin D; Zheng H; Tang Y; Li W; Zhou J; Liu L; Yu X; Duan H; Zhou Y; Li Z; Fang Z; Luo Y; Carter BZ; Xu B; Zha J
Cell Death Dis; 2023 Aug; 14(8):573. PubMed ID: 37644011
[TBL] [Abstract][Full Text] [Related]
3. TRIB3 destabilizes tumor suppressor PPARα expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Luo X; Zhong L; Yu L; Xiong L; Dan W; Li J; Ye J; Chu X; Liu C; Liu B
Life Sci; 2020 Sep; 257():118021. PubMed ID: 32621919
[TBL] [Abstract][Full Text] [Related]
4. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
5. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
6. TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells.
Wang H; Sica RA; Kaur G; Galbo PM; Jing Z; Nishimura CD; Ren X; Tanwar A; Etemad-Gilbertson B; Will B; Zheng D; Fooksman D; Zang X
Nat Commun; 2024 Jan; 15(1):11. PubMed ID: 38167704
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
8. High PD‑L1 expression drives glycolysis via an Akt/mTOR/HIF‑1α axis in acute myeloid leukemia.
Ma P; Xing M; Han L; Gan S; Ma J; Wu F; Huang Y; Chen Y; Tian W; An C; Sun H; Sun L
Oncol Rep; 2020 Mar; 43(3):999-1009. PubMed ID: 32020232
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
10. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
[TBL] [Abstract][Full Text] [Related]
11. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
12. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
13. Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia.
Shingai Y; Yokota T; Okuzaki D; Sudo T; Ishibashi T; Doi Y; Ueda T; Ozawa T; Nakai R; Tanimura A; Ichii M; Shibayama H; Kanakura Y; Hosen N
Stem Cells; 2021 Jun; 39(6):723-736. PubMed ID: 33539590
[TBL] [Abstract][Full Text] [Related]
14. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
[TBL] [Abstract][Full Text] [Related]
15. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
[TBL] [Abstract][Full Text] [Related]
16. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
[TBL] [Abstract][Full Text] [Related]
17. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
19. DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax.
Ye S; Xiong F; He X; Yuan Y; Li D; Ye D; Shi L; Lin Z; Zhao M; Feng S; Zhou B; Weng H; Hong L; Ye H; Gao S
Theranostics; 2023; 13(1):77-94. PubMed ID: 36593968
[No Abstract] [Full Text] [Related]
20. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
